切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2022, Vol. 16 ›› Issue (03) : 205 -209. doi: 10.3877/cma.j.issn.1674-0793.2022.03.009

论著

肝切除术中不同断肝方式治疗多病灶原发性肝癌的临床效果研究
周保富1,(), 吴乐乐1, 李永红1, 胡世超1   
  1. 1. 237000 六安,安徽医科大学附属六安医院普外科(肝胆外科)
  • 收稿日期:2021-10-28 出版日期:2022-06-01
  • 通信作者: 周保富

Effect of different liver cutting methods in hepatectomy for multifocal primary liver cancer

Baofu Zhou1,(), Lele Wu1, Yonghong Li1, Shichao Hu1   

  1. 1. Department of General Surgery (Hepatobiliary Surgery), Lu’ an Hospital Affiliated to Anhui Medical University, Lu’ an 237000, China
  • Received:2021-10-28 Published:2022-06-01
  • Corresponding author: Baofu Zhou
引用本文:

周保富, 吴乐乐, 李永红, 胡世超. 肝切除术中不同断肝方式治疗多病灶原发性肝癌的临床效果研究[J/OL]. 中华普通外科学文献(电子版), 2022, 16(03): 205-209.

Baofu Zhou, Lele Wu, Yonghong Li, Shichao Hu. Effect of different liver cutting methods in hepatectomy for multifocal primary liver cancer[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(03): 205-209.

目的

探讨肝切除术中不同断肝方式治疗多病灶原发性肝癌的临床效果,分析射频消融术(RFA)辅助断肝治疗多病灶原发性肝癌的优势。

方法

回顾性分析2014年1月至2019年12月于安徽医科大学附属六安医院确诊为多病灶原发性肝癌的156例患者临床资料,其中72例为肝切除术中应用RFA辅助断肝(RFA组),84例采用传统肝切除术(对照组)。观察两组患者手术时间、肝门阻断时间、术中出血量及术后住院时间等手术相关指标;对比两组患者手术前后丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、甲胎蛋白(AFP)、总胆酸(TBA)及总胆红素(TBIL)等肝功能指标水平,以及术后并发症、术后生存情况。

结果

与对照组相比,RFA组患者的手术时间、肝门阻断时间、术后住院时间显著缩短,术中出血量亦明显减少,差异均有统计学意义(P<0.05)。术前两组患者肝功能指标ALT、AST、AFP、TBA及TBIL水平比较,差异无统计学意义,术后7 d时均显著下降(P<0.05),且RFA组ALT、AST、AFP水平显著低于对照组(P<0.05)。术后RFA组并发症发生率为5.56%(4/72),低于对照组的15.48%(χ2=3.930,P=0.047)。对照组患者术后1、3、5年累积总生存率和无病生存率分别为92.85%、64.28%、57.14%和88.10%、58.33%、47.62%;RFA组术后1、3、5年累积生存率和无病生存率分别为100.0%、87.50%、69.44%和95.83%、75.00%、61.11%。两组术后3、5年累积总生存率和1、3、5年累积无病生存率比较,差异均有统计学意义(P<0.05)。

结论

在肝切除术中应用RFA辅助断肝,对于治疗多病灶原发性肝癌患者具有出血少、手术并发症发生率低、远期生存率高等优势,可在临床中大力推广。

Objective

To explore the clinical effect of different liver transection methods in hepatectomy for multifocal primary liver cancer, and analyze the advantages of radiofrequency ablation (RFA) assisted liver transection in hepatectomy.

Methods

The clinical data of 156 patients with multifocal primary liver cancer diagnosed in Lu’ an Hospital Affiliated to Anhui Medical University from January 2014 to December 2019 were analyzed retrospectively. Among them, 72 cases were treated with RFA assisted liver transection during hepatectomy (RFA group), and 84 cases only underwent hepatectomy as the control group. The operation time, hilar blocking time, intraoperative bleeding and postoperative hospital stay were observed. The levels of liver function indexes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alpha-fetoprotein (AFP), total cholic acid (TBA) and total bilirubin (TBIL) before and after operation, as well as postoperative complications and postoperative survival were compared between the two groups.

Results

Compared with the control group, the operation time, hilar blocking time, postoperative hospital stay and intraoperative bleeding in RFA group were significantly shorter or less (all P<0.05). There were no significant differences in the levels of ALT, AST, AFP, TBA and TBIL between the two groups before operation, and the corresponding liver function indexes of all patients were significantly decreased on the 7th day after surgery (P<0.05). In addition, the levels of ALT, AST and AFP in the RFA group after surgery were significantly different from those in the control group (P<0.05). The incidence of complications in RFA group was 5.56% (4/72), which was lower than 15.48% in the control group (χ2=3.930, P=0.047). The cumulative overall survival rate and disease-free survival rate at 1-, 3- and 5-year were 92.85%, 64.28%, 57.14% and 88.10%, 58.33% and 47.62% in the control group; 100.0%, 87.50%, 69.44%, and 95.83%, 75.00%, and 61.11% in RFA group, respectively. There were significant differences between the two groups in the 3-, 5-year cumulative overall survival rate and 1-, 3-, 5-year cumulative disease-free survival rate (P<0.05).

Conclusions

RFA assisted liver transection in hepatectomy has the advantages of less bleeding, lower incidence of postoperative complications and higher long-term survival rate for the treatment of paitents with multifocal primary liver cancer. It can be used in the combination with hepatectomy in clinical application and has high promotion value.

表1 两组多病灶原发性肝癌患者一般资料比较
表2 两组多病灶原发性肝癌患者手术相关指标比较(±s
表3 两组多病灶原发性肝癌患者手术前后肝功能指标比较(±s
图1 两组多病灶原发性肝癌患者5年累积总生存率和无病生存率比较
[1]
Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.
[2]
Zheng R, Wei W, Chen W, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030[J]. Chin J Cancer Res, 2018, 30(6): 571-579.
[3]
Chen SW, Xia HX, Fan QQ, et al. Precise hepatectomy in the treatment of patients with primary liver cancer[J]. J Biol Regul Homeost Agents, 2019, 33(1): 225-230.
[4]
Picchi SG, Lassandro G, Bianco A, et al. RFA of primary and metastatic lung tumors: long-term results[J]. Med Oncol, 2020, 37(5): 35.
[5]
Ye QW, Pang SJ, Yang N, et al. Safety and efficacy of radiofrequency ablation for solitary hepatocellular carcinoma (3-5 cm):A propensity score matching cohort study[J]. J Gastrointest Surg, 2019, 23(2): 1549-1558.
[6]
郝以杰, 牛哲禹, 卢俊. 循环肿瘤细胞在肝癌中的研究及应用进展[J]. 中国肿瘤临床, 2019, 46(13): 690-693.
[7]
Cai J, Zheng J, Xie Y, et al. Laparoscopic repeat hepatectomy for treating recurrent liver cancer[J]. J Minim Access Surg, 2021, 17(1): 1-6.
[8]
Gavriilidis P, Askari A, Azoulay D. Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: A systematic review and Meta-analysis[J]. Hpb, 2017, 19(1): 3-9.
[9]
Lee HW, Lee JM, Yoon JH, et al. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma[J]. Ann Surg Treat Res, 2018, 94(2): 74-82.
[10]
Chua DW, Koh YX, Syn NL, et al. Repeat hepatectomy versus radiofrequency ablation in management of recurrent hepatocellular carcinoma: An average treatment effect analysis[J]. Ann Surg Oncol, 2021, 28(12): 7731-7740.
[11]
杨海棠, 杨磊, 杨凯歌. 腹腔镜超声辅助射频消融术治疗原发性肝癌的临床疗效研究[J]. 癌症进展, 2018, 16(5): 619-622.
[12]
Kang TW, Lim HK, Cha DI. Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma[J]. Clin Mol Hepatol, 2017, 23(1): 95-101.
[13]
Sandri GB, Werra ED, Masciana G, et al. Liver resection for hepatocellular carcinoma, are we going to dismiss the traditional approach?[J]. Ann Laparosc Endosc Surg, 2017, 2(34): 1-6.
[14]
Matsumoto M, Yanaga K, Shiba H, et al. Treatment of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma[J]. Ann Gastroenterol Surg, 2021, 5(4): 538-552.
[15]
Li B, Qin Y, Qiu Z, et al. A cohort study of hepatectomy-related complications and prediction model for postoperative liver failure after major liver resection in 1,441 patients without obstructive jaundice[J]. Ann Transl Med, 2021, 9(4): 305-312.
[16]
何建新, 王永波, 何文平, 等. 射频消融术辅助部分肝切除术治疗原发性肝癌的效果及复发率随访研究[J]. 肝胆外科杂志, 2017, 25(2): 126-129.
[17]
李玉民, 马臻, 陈昊. 原发性肝癌射频消融治疗[J/CD]. 中华肝脏外科手术学电子杂志, 2017, 6(5): 337-342.
[18]
Chen CL. Does artificial ascites induce heat sink effect or electricity steal effect in the radiofrequency ablation of superficial liver tumor?[J]. Adv Dig Med, 2019, 6(4): 141-143.
[1] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[2] 钟锴, 蒋铁民, 张瑞青, 吐尔干艾力·阿吉, 邵英梅, 郭强. 加速康复外科在肝囊型棘球蚴病肝切除术中的应用分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 425-429.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 杨建波, 马欢, 黄小梅, 刘华柱. 结肠镜辅助下EMR、CSP和RFA术治疗直径<1cm结直肠息肉的疗效和安全性比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 76-79.
[5] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[6] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[7] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[8] 臧宇, 姚胜, 朱新勇, 戎世捧, 田智超. 低温等离子射频消融治疗腹壁疝术后补片感染的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 687-692.
[9] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[10] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[11] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[12] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[13] 杭轶, 杨小勇, 李文美, 薛磊. 可控性低中心静脉压技术在肝切除术中应用的最适中心静脉压[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 813-817.
[14] 韩俊岭, 王刚, 马厉英, 连颖, 徐慧. 维生素D 联合匹维溴铵治疗腹泻型肠易激综合征患者疗效及对肠道屏障功能指标的影响研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 560-564.
[15] 广东省护士协会介入护士分会, 广东省医师协会介入医师分会. 原发性肝癌低血糖患者护理规范管理专家共识[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 709-714.
阅读次数
全文


摘要